Decreased serum glucose levels after initiation of methylphenidate in a patient status post-cerebellar tumour resection: A potential interaction with glipizide

Clinical Drug Investigation

Volumn 27, Issue 10, 2007, Pages 719-725

  Gontkovsky, Samuel T ^a,b,c   Nevels, Robert ^a   McDonald, Nicholas B ^d   Winkelmann, Michael H ^b  

^a JACKSON STATE UNIVERSITY   (United States)

^b METHODIST REHABILITATION CENTER   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d American Education Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ASCORBIC ACID; BISACODYL; DIAZEPAM; GLIPIZIDE; GLUCOSE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; INSULIN; METAXALONE; METFORMIN; METHYLPHENIDATE;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CASE REPORT; CEREBELLUM TUMOR; COGNITIVE DEFECT; COMORBIDITY; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG SAFETY; FEMALE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBELLAR NEOPLASMS; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; DRUG LABELING; FEMALE; GLIPIZIDE; HUMANS; METHYLPHENIDATE; RISK MANAGEMENT; SULFONYLUREA COMPOUNDS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 34748869753     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727100-00007     Document Type: Article

References (28)

1. Hampshire J, Moraru E, Altszuler N. On the mechanism of hyperglycemia and stimulation of growth hormone secretion by L-dopa. Pharmacology 1978; 17: 138-48
2. Rayfield EJ, George DT, Eichner HL, et al. L-dopa stimulation of glucagons secretion in man. N Engl J Med 1975; 293: 589-91
3. Schmidt MJ. Dopamine agonist-induced hyperglycemia in rats: effects of lergotrile mesylate. Eur J Pharmacol 1979; 59: 95-101
4. Sirtori CR, Bolme P, Azarnoff DL. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med 1972; 287: 729-33
5. Hakanson R, Lundquist RI, Rerup C. On the hyperglycemic effect of dopa and dopamine. Eur J Pharmacol 1967; 1: 114-9
6. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of methylphenidate. Am J Psychiatry 1998; 155: 1325-31
7. Wax P. Analeptic use in clinical toxicology: a historical appraisal. Clin Toxicol 1997; 35: 203-9
8. Satterfield JH, Schell AM, Barb SD. Potential risk of prolonged administration of stimulant medication for hyperactive children. J Dev Behav Pediatr 1980; 1: 102-7
9. Greeley GH, Kizer JS. The effects of chronic methylphenidate treatment on growth and endocrine function in the developing rat. J Pharmacol Exp Ther 1980; 215: 545-51
10. Satterfield JH, Cantwell DP, Schell AM, et al. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry 1979; 36: 212-7
11. Kajs-Wyllie M. Ritalin revisited: does it really help in neurological injury? J Neurosci Nurs 2002; 34: 303-13
12. Whyte J, Vaccaro M, Grieb-Neff P, et al. Psychostimulant use in the rehabilitation of individuals with traumatic brain injury. J Head Trauma Rehabil 2002; 17: 284-99
13. Patrick PD, Buck ML, Conaway MR, et al. The use of dopamine enhancing medications with children in low response states following brain injury. Brain Inj 2003; 17: 497-506
14. Fernandez F, Adams F. Methylphenidate treatment of patients with head and neck cancer. Head Neck Surg 1986; 8: 296-300
15. Meyers CA, Weitzner MA, Valentine AD, et al. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients. J Clin Oncol 1998; 16: 2522-7
16. Weitzner MA, Meyers CA, Valentine AD. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 1995; 7: 347-50
17. Gontkovsky ST, Winkelmann MH. Improved cognition with methylphenidate status post cerebellar tumor resection: a case report. J Cogn Rehabil 2006; 24: 5-8
18. Hubbard JR, Albanese RP. Primary care medicine for specialists and non-specialists: a practitioner's guide. New York: Plenum, 2002
19. Reiss BS, Evans ME, Broyles BE. Pharmacological aspects of nursing care. New York: Thompson Delmar Learning, 2001
20. Cerrulli TR, Alkoc SC, Salzman C. Effects of psychotropic medications on pancreatic function: a review. Harv Rev Psychiatry 1999; 7: 54-60
21. Volkow ND, Wang GJ, Fowler JS, et al. Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. Am J Psychiatry 1997; 154: 50-5
22. Gilman S, Adams K, Koeppe RA, et al. Cerebellar and frontal hypometabolism in alcoholic cerebellar degeneration studied with positron emission tomography. Ann Neurol 2004; 28: 775-85
23. Sayler JL, Tennison L, Mitchell D. Physiological and behavioral effects of d-threo-methylphenidate hydrochloride in male Wistar-Kyoto and spontaneously hypertensive rats. Am J Undergraduate Res 2003; 2: 13-20
24. Physicians' desk reference guide to drug interactions, side effects, and indications. 2nd ed. Montvale (NJ): Thomson Healthcare, 2007
25. Physicians' desk reference. 61st ed. Montvale (NJ): Thomson Healthcare, 2007
26. Mokdad A, Ford E, Bowman B, et al. Diabetes trends in the US: 1990-1998. Diabetes Care 2000; 23: 1278-83
27. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes in the United States. Rev. ed. Atlanta (GA): Centers for Disease Control and Prevention, 1998
28. Bruce TJ. Will the FDA attempt to change stimulant prescribing practices for ADHD? Clin Psychol 2006; 59: 15